A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant compared with Fulvestrant, both combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-NEGATIVE Advanced Breast Cacncer with Resistance to Prior Adjuvant Endocrine Therapy
